Atria Investments Inc Sells 664 Shares of iShares Biotechnology ETF $IBB

Atria Investments Inc trimmed its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 29.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,596 shares of the financial services provider’s stock after selling 664 shares during the period. Atria Investments Inc’s holdings in iShares Biotechnology ETF were worth $202,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Citigroup Inc. raised its stake in iShares Biotechnology ETF by 88.5% during the 1st quarter. Citigroup Inc. now owns 3,208,144 shares of the financial services provider’s stock valued at $410,322,000 after buying an additional 1,505,976 shares during the last quarter. Millennium Management LLC grew its holdings in shares of iShares Biotechnology ETF by 140.8% in the first quarter. Millennium Management LLC now owns 41,676 shares of the financial services provider’s stock worth $5,330,000 after acquiring an additional 143,893 shares during the period. Jones Financial Companies Lllp grew its holdings in shares of iShares Biotechnology ETF by 763.3% in the first quarter. Jones Financial Companies Lllp now owns 151,265 shares of the financial services provider’s stock worth $19,347,000 after acquiring an additional 133,744 shares during the period. Ashton Thomas Private Wealth LLC increased its position in iShares Biotechnology ETF by 769.9% during the second quarter. Ashton Thomas Private Wealth LLC now owns 63,691 shares of the financial services provider’s stock valued at $8,058,000 after acquiring an additional 56,369 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. lifted its holdings in iShares Biotechnology ETF by 35.0% in the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 116,115 shares of the financial services provider’s stock valued at $14,690,000 after acquiring an additional 30,115 shares during the period. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ:IBB opened at $163.32 on Friday. The stock’s 50-day simple moving average is $150.58 and its two-hundred day simple moving average is $136.68. iShares Biotechnology ETF has a 52-week low of $107.43 and a 52-week high of $166.29.

iShares Biotechnology ETF Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 19th. Investors of record on Tuesday, September 16th were issued a $0.0828 dividend. The ex-dividend date of this dividend was Tuesday, September 16th. This represents a $0.33 dividend on an annualized basis and a dividend yield of 0.2%.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.